naloxone and Leishmaniasis--Cutaneous

naloxone has been researched along with Leishmaniasis--Cutaneous* in 2 studies

Other Studies

2 other study(ies) available for naloxone and Leishmaniasis--Cutaneous

ArticleYear
Naloxone Diminishes the Virulence and Modifies the Cellular Immune Responses of BALB/c Mice Infected with Leishmania major.
    Acta parasitologica, 2021, Volume: 66, Issue:2

    Leishmania major-infected BALB/c mice display strong susceptibility to the infection due to the induction of Th2 response. The aim of this study was to assess the effects of naloxone on virulence of L. major in BALB/c mice and the ensued cellular immune response.. The effects of injection of a single dose of naloxone in the footpad of L. major-infected BALB/c mice were investigated by evaluating the lesion sizes, the parasite burden, cell proliferation, secreted cytokines (IFN-γ, IL-4, IL-10 and IL-12) and their genes expressions due to naloxone treatment while the untreated mice were used as a control.. Significantly lower lesion sizes and less parasite burden were measured in the treated mice. Significantly decreased productions of IFN-γ, IL-12, IL-4, and IL-10 were also observed in the treated mice at week 4 post-infection while the production IL-10 remained significantly hindered till 8 weeks post-infection.. Our data indicated that although the treatment of L. major-infected BALB/c mice with a single dose of naloxone was unable to improve the cellular immune response, it led to lower virulence, confirmed by significantly reduced lesions and parasite load.

    Topics: Animals; Immunity, Cellular; Leishmania major; Leishmaniasis, Cutaneous; Mice; Mice, Inbred BALB C; Naloxone; Virulence

2021
The opioid antagonist naloxone inhibits Leishmania major infection in BALB/c mice.
    Experimental parasitology, 2012, Volume: 130, Issue:1

    BALB/c mice are susceptible to develop non-healing, progressive infection with Leishmania major (L. major) due to the development of a non-protective Th2 response. Resistance to L. major infection is dependent to Th1 response. Treatment of mice with the opioid antagonist naloxone can promote the activation of Th1 responses. Here we study the effect of chronic administration of various doses of naloxone on susceptibility of BALB/c mice to L. major infection. Our results showed that naloxone has dose-dependent biphasic effect on L. major infection in BALB/c mice. While administration of 1mg/kg × 2/day tends to exacerbate the local reaction to L. major infection, treatment with 10mg/kg × 2/day of naloxone suppresses the local reaction and progress of infection. On the other hand treatment of mice with middle dose (5mg/kg whether 1 or 2 times per day) does not have significant effect on the infection. This study demonstrates that administration of high dose of naloxone could improve protection against L. major infection in BALB/c mice, presumably by modulation in Th1/Th2 balance or by affecting macrophages through binding to Toll-like receptors.

    Topics: Animals; Cells, Cultured; Dose-Response Relationship, Drug; Interferon-gamma; Interleukin-4; Leishmania major; Leishmaniasis, Cutaneous; Lymph Nodes; Male; Mice; Mice, Inbred BALB C; Naloxone; Narcotic Antagonists

2012